DK

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]

Retrieved on: 
Thursday, May 12, 2022
Diabetes, Hypoglycemia, Patient, Boehringer Ingelheim, Person, DKK, DK, Nasdaq, Adult, AstraZeneca, Documentation, Zealand Pharma, Pharmaceutical industry

Copenhagen, DK and Boston, MA, May 12, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, May 12, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.
  • 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

Retrieved on: 
Thursday, May 12, 2022
Diabetes, Hypoglycemia, Patient, Boehringer Ingelheim, Person, DK, Nasdaq, Adult, AstraZeneca, Zealand Pharma, Pharmaceutical industry

Copenhagen, DK and Boston, MA, May 12, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, May 12, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.
  • 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022

Retrieved on: 
Tuesday, May 10, 2022
Hypoglycemia, Nasdaq, NASDAQ, Credit Suisse, Patient, Boehringer Ingelheim, Diabetes, Adult, Zealand Pharma, Capital market, DK, AstraZeneca, Fine chemical

Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022

Key Points: 
  • Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
    Copenhagen, DK and Boston, MA, May 10 2022 Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • The above information contains forward-looking statements that provide Zealand Pharmas expectations or forecasts of future events.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company’s Refocused Strategy

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, Investment, Private Securities Litigation Reform Act, Senior, Nasdaq, Failure, Structured Product Labeling, Patient, Boehringer Ingelheim, LIBOR, History, Advertising, Zealand Pharma, Sale, DK, Intellectual property, AstraZeneca, Solution, Research, Acquisition, Fine chemical, Security (finance), Pharmaceutical industry

20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced an amendment to its existing financing agreement with Oberland Capital Management LLC (Oberland Capital).

Key Points: 
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced an amendment to its existing financing agreement with Oberland Capital Management LLC (Oberland Capital).
  • The amended terms of the agreement are:
    Zealand to repurchase $50.0 million of note principal with a 1.2x prepayment premium.
  • Todays agreement gives us a strong financial foundation to be able to deliver on our R&D priorities, said Matthew Dallas, Senior Vice President and Chief Financial Officer at Zealand Pharma.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

US Plan to Increase Domestic Energy While Cutting Emissions is Going to Need a Lot of Help

Retrieved on: 
Friday, April 29, 2022
Permian, Soma, Solution, Shell, Water, Sale, Former, Public expenditure, CORT, TSX Venture Exchange, OTC, Delek, NASDAQ, Sand, NYSE, Director, Tier 1, Growth, Company, Morgan Stanley, Heart, Carbon, NexTier Bank, ESG, CEO, TSX, LLC, EPA, Indian stock exchange, Technology, DK, Piper Sandler Companies, Board, NPV, Government, Delaware Basin, Broadlands, Recycling, Carbon footprint, Acquisition, Engineering, Nano, Vertex, News, NEX, Renewable energy, Oil, Health insurance, Financial services, Management, Petroteq Energy, BC

VANCOUVER, BC, April 29, 2022 /PRNewswire/ -- USA News Group –Soaring gas prices and threats to energy security have forced the US government to embrace domestic fossil fuels, just one year after pledging to restrict drilling on public lands and launching an ambitious clean energy agenda. As oil producers in petroleum hubs like Texas prepare to increase production, activists are voicing their concern over the potentially higher emissions that could follow. Finding an acceptable balance for domestic production and emissions will likely require innovation and prudence from the oil sector, with recent developments coming from oil tech, energy service providers and producers, such as Petroteq Energy, Inc. (OTCPK:PQEFF), Delek US Holdings, Inc. (NYSE:DK), Vertex Energy Inc. (NASDAQ:VTNR), ChampionX Corporation (NASDAQ:CHX), and NexTier Oilfield Solutions Inc. (NYSE:NEX).

Key Points: 
  • As oil producers in petroleum hubs like Texas prepare to increase production, activists are voicing their concern over the potentially higher emissions that could follow.
  • The CORT system utilizes a conventional sand dryer modified for service with petrochemical solvents in a closed loop.
  • Houston-based Vertex Energy Inc. (NASDAQ:VTNR) recently completed the acquisition of a 90,000 barrels-per-day refinery in Mobile, Alabama from Shell.
  • "Commodity prices are giving our customers confidence to increase consumption of our services in a market where the utilization of available frac equipment is already high.

US Plan to Increase Domestic Energy While Cutting Emissions is Going to Need a Lot of Help

Retrieved on: 
Friday, April 29, 2022
Permian, Soma, Solution, Shell, Water, Sale, Former, Public expenditure, CORT, TSX Venture Exchange, OTC, Delek, NASDAQ, Sand, NYSE, Director, Tier 1, Growth, Company, Morgan Stanley, Heart, Carbon, NexTier Bank, ESG, CEO, TSX, LLC, EPA, Indian stock exchange, Technology, DK, Piper Sandler Companies, Board, NPV, Government, Delaware Basin, Broadlands, Recycling, Carbon footprint, Acquisition, Engineering, Nano, Vertex, News, NEX, Renewable energy, Oil, Health insurance, Financial services, Management, Petroteq Energy, BC

VANCOUVER, BC, April 29, 2022 /PRNewswire/ -- USA News Group –Soaring gas prices and threats to energy security have forced the US government to embrace domestic fossil fuels, just one year after pledging to restrict drilling on public lands and launching an ambitious clean energy agenda. As oil producers in petroleum hubs like Texas prepare to increase production, activists are voicing their concern over the potentially higher emissions that could follow. Finding an acceptable balance for domestic production and emissions will likely require innovation and prudence from the oil sector, with recent developments coming from oil tech, energy service providers and producers, such as Petroteq Energy, Inc. (OTCPK:PQEFF), Delek US Holdings, Inc. (NYSE:DK), Vertex Energy Inc. (NASDAQ:VTNR), ChampionX Corporation (NASDAQ:CHX), and NexTier Oilfield Solutions Inc. (NYSE:NEX).

Key Points: 
  • As oil producers in petroleum hubs like Texas prepare to increase production, activists are voicing their concern over the potentially higher emissions that could follow.
  • The CORT system utilizes a conventional sand dryer modified for service with petrochemical solvents in a closed loop.
  • Houston-based Vertex Energy Inc. (NASDAQ:VTNR) recently completed the acquisition of a 90,000 barrels-per-day refinery in Mobile, Alabama from Shell.
  • "Commodity prices are giving our customers confidence to increase consumption of our services in a market where the utilization of available frac equipment is already high.

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

Retrieved on: 
Friday, April 22, 2022
AstraZeneca, Zealand Pharma, Person, Diabetes, Nasdaq, Boehringer Ingelheim, Hypoglycemia, DK, Patient, Adult, Pharmaceutical industry

Copenhagen, DK and Boston, MA, April 22, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, April 22, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.
  • 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Delek Logistics Partners, LP to Host First Quarter 2022 Conference Call on May 3rd

Retrieved on: 
Wednesday, April 20, 2022
NYSE, Review, Partnership, Multimedia, DKL, Marketing, DK, Delek, Twitter, Natural gas, Public relations, LP, Delek US

BRENTWOOD, Tenn., April 20, 2022 /PRNewswire/ -- Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced that the Partnership intends to issue a press release summarizing first quarter 2022 results before the U.S. stock market opens on Tuesday, May 3, 2022.

Key Points: 
  • BRENTWOOD, Tenn., April 20, 2022 /PRNewswire/ -- Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced that the Partnership intends to issue a press release summarizing first quarter 2022 results before the U.S. stock market opens on Tuesday, May 3, 2022.
  • A conference call to discuss first quarter 2022 results is scheduled to begin at 9:30 a.m. CT (10:30 a.m.
  • Investors may also wish to listen to Delek US Holdings, Inc.'s (NYSE: DK) ("Delek US") first quarter 2022 earnings conference call on Tuesday, May 3, 2022 at 11:00 a.m. CT (12:00 p.m.
  • Market trends and information disclosed by Delek US may be relevant to Delek Logistics, as it is a consolidated subsidiary of Delek US.

Delek US Holdings to Host First Quarter 2022 Conference Call on May 3rd

Retrieved on: 
Wednesday, April 20, 2022
Dorado, Marketing, DK, Natural gas, Gulf Oil LP, Company, Delek, NYSE, LP, Multimedia, Partnership, DKL, Video game, Petroleum, Delek US

A conference call to discuss first quarter 2022 results is scheduled to begin at 11:00 a.m. CT (12:00 p.m.

Key Points: 
  • A conference call to discuss first quarter 2022 results is scheduled to begin at 11:00 a.m. CT (12:00 p.m.
  • Investors may also wish to listen to Delek Logistics Partners, LP's (NYSE: DKL) ("Delek Logistics") first quarter 2022 earnings conference call on Tuesday, May 3, 2022 at 9:30 a.m. CT (10:30 a.m.
  • Market trends and information disclosed by Delek Logistics may be relevant to the logistics segment reported by Delek US.
  • Delek US and its affiliates also own the general partner and an approximate 80 percent limited partner interest in Delek Logistics.

Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022

Retrieved on: 
Thursday, April 7, 2022
Hypoglycemia, Capital Group Companies, LLP, NASDAQ, Adult, Capital, DK, AstraZeneca, Boehringer Ingelheim, Diabetes, Zealand Pharma, Nasdaq, Patient, Fine chemical

Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022

Key Points: 
  • Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022
    Copenhagen, DK and Boston, MA, April 7, 2022 Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.